Search - tctmd.com

Displaying 181 - 200 of 327

Sort: Relevancy | Date

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

CV Risk Factors in Youth May Prove Indelible for Later CAD

Marcus A. Banks

July 17, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

Elevated Non-HDL Cholesterol Levels Persist From Youth to Middle Age

Marcus A. Banks

July 03, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Daily News

No Free Brunch? Eggs Once Again Feel the Scramble in New, Large Observational Study

Caitlin E. Cox

March 22, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Advertisement

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

CV Risk Factors in Youth May Prove Indelible for Later CAD

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Elevated Non-HDL Cholesterol Levels Persist From Youth to Middle Age

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

No Need for Niacin? Meta-analysis Argues the End Is Nigh

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

No Free Brunch? Eggs Once Again Feel the Scramble in New, Large Observational Study

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content